Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years

Collaborative Study to Assess the Effects of Treatment With Recombinant Growth Hormone Saizen® in the Prevention of Short Stature in Young Girls Suffering From Turner Syndrome Before the Age of 4 Years. Original French Title: Etude Collaborative Pour apprécier Les Effets du Traitement Par l'Hormone de Croissance Recombinante SAIZEN® Dans le Retard de Croissance de la Fillette Atteinte de Syndrome de Turner Avant l'âge de 4 Ans

The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years. After 4 years of treatment, height in these girls will be compared with an historical control group of untreated girls with Turner Syndrome, matched for age and height at baseline.

Inclusion Criteria:

• Young girls with turner syndrome proved by karyotype
• Growth hormone secretion confirmed with ornithin stimulation test
• Normal glucidic metabolism confirmed by assessment of HbA1c
• None associated severe pathology which could have impact on growth (i.e. renal insufficiency, decompensated heart failure)
• No previous or associated treatment with anabolic or sexual steroids
• Known parental height

Exclusion Criteria:

• Severe associated pathology with impact on growth
• Concomitant treatment with impact on growth
• Previous or associated treatment with anabolic steroids
• Associated growth hormone deficiency